Stockwinners Market Radar for March 04, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EST VEON Ltd trading halted, news pending

18:17 EST GAP Airports reports preliminary February traffic up 24.3% y/y - Grupo Aeroportuario del Pacifico, S.A.B. announces preliminary terminal passenger traffic figures for the month of February 2023, compared with the same period of 2022. For February 2023, the total number of terminal passengers at GAP's 12 Mexican airports increased by 21.8%, compared to the same period of 2022. Puerto Vallarta, Guadalajara, Los Cabos, and Tijuana presented an increase in passenger traffic of 31.9%, 26.0%, 24.5%, and 12.5% respectively, compared to February 2022. On the other hand, Montego Bay increase by 49.5% and Kingston 43.0%, compared to 2022.

17:40 EST ROC Energy Acquisition announces second extension of combination deadline - ROC Energy Acquisition Corp. announced that its sponsor, ROC Energy Holdings LLC, has requested that the company extend the date by which the company must consummate a business combination from March 6, 2023 to June 6, 2023. The Extension is the second of two three-month extensions permitted under the company's governing documents. In connection with the Extension, the Sponsor has notified the company that it intends to deposit an aggregate of $2,070,000 into the company's trust account on or before March 6, 2023. The Extension provides the company with additional time to complete its initial business combination.

17:31 EST S&P announces changes to S&P 400, 600 indices at open on 3/20 - Axalta Coating Systems (AXTA), Autoliv (ALV), Starwood Property Trust (STWD), SouthState (SSB), Chord Energy (CHRD), Advanced Drainage Systems (WMS), Hilton Grand Vacations (HGV), Hertz Global Holdings (HTZ), Aramark (ARMK) and US Foods Holding (USFD) will replace SL Green Realty (SLG), Cracker Barrel Old Country Store (CBRL), ViaSat (VSAT), Washington Federal (WAFD), Dycom Industries (DY), Kennametal (KMT), JBG Smith Properties (JBGS), Pebblebrook Hotel Trust (PEB), Hanesbrands (HBI) and Tandem Diabetes Care (TNDM) respectively in the S&P MidCap 400. All constituents being removed from the S&P MidCap 400 will be added to the S&P SmallCap 600 replacing The Pennant Group (PNTG), Unisys (UIS), Organogenesis Holdings (ORGO), Surmodics (SRDX), Hersha Hospitality Trust (HT), Park Aerospace (PKE), Granite Point Mortgage Trust (GPMT), Industrial Logistics Properties Trust (ILPT), OptimizeRx (OPRX), and ZimVie (ZIMV) respectively.

17:18 EST Lumen to replace Bed Bath & Beyond in S&P 600 at open on 3/20

17:11 EST Lockheed Martin awarded $214.5M Navy contract - Lockheed Martin was awarded a $214.5M indefinite-delivery/indefinite quantity, cost-plus-fixed-fee, cost-plus-incentive-fee, and cost type contract for multinational early start engineering efforts including planning and advance studies, requirements development, and performance assessment of the planned modernization and new combat system capabilities selection for current and future International Partner ships operating AEGIS. This contract involves Foreign Military Sales to Canada and other countries. Work is expected to be completed by December. Foreign Military Sales funds in the amount of $28.08Mwill be obligated on the first task order at time of award and will not expire at the end of the current fiscal year. This contract was not competitively procured in accordance with 10 U.S. Code 2304 and 10 U.S. Code 2304. The Naval Sea Systems is the contracting activity.

17:09 EST BAE Systems awarded $245.65M Army contract - BAE Systems was awarded a $245.65M cost-no-fee, cost-sharing contract for the procurement of early-order material in support of the future purchase of Armored Multi-Purpose Vehicles, or AMPV, and facility-capacity-expansion efforts to increase AMPV production. Bids were solicited via the internet with one received. Work will be performed in York, Pennsylvania, with an estimated completion date of December 31, 2024. FY22 and FY23 weapons and tracked combat vehicle procurement, Army funds in the amount of $245.65M were obligated at the time of the award. U.S. Army Contracting is the contracting activity.

16:53 EST Trian Fund cuts Wendy's stake to 17.85% from 19.52% - In a regulatory filing, Trian Fund Management disclosed a 17.85% stake in Wendy's, which represents 37,957,224 common shares. Trian previously reported a 19.52% stake in Wendy's in January 2023. The filing allows for activism.

16:45 EST Procore CLO Singer sells 8,390 common shares - In a regulatory filing, Procore Technologies chief legal officer Benjamin Singer disclosed the sale of 8,390 common shares of the company on March 1 at a price of $65.04 per share.

16:36 EST Express COO Matthew Moellering to retire, effective May 5 - Express announced the retirement of the company's President & COO, Matthew Moellering, effective May 5. The company has retained executive search and leadership advisory firm Spencer Stuart to conduct an external search for Moellering's replacement.

16:32 EST Quest Diagnostics CEO James Davis to succeed Steve Rusckowski as chairman - Quest Diagnostics announced that its board of directors elected James Davis, the company's CEO and president, to serve in the additional position of chairman of the board of directors, effective April 1. Davis, who joined the company in 2013 and assumed the role of CEO, president and director on November 1, 2022, will succeed former CEO Steve Rusckowski, who remains chairman through March 31.

16:18 EST Comerica selects Ameriprise as new investment program provider - Ameriprise Financial (AMP) and Comerica Bank (CMA) announced that Ameriprise Financial Services, LLC and Comerica Bank have signed an agreement for Ameriprise to become Comerica's new investment program provider. As part of the arrangement, Comerica and certain affiliates will transition support of specific insurance, brokerage and investment advisory activities currently conducted by Comerica's broker-dealer subsidiary to the Ameriprise Financial Institutions Group. The transaction is expected to close by the end of the year. Headquartered in Dallas, Comerica has approximately 100 financial advisors who are part of a broader team of nearly 800 who support the wealth management business throughout Texas and in Michigan, California, Florida, Arizona and the Carolinas. Comerica's wealth management division manages approximately $195B in assets, approximately $18B of which is managed by its securities business and is expected to be supported by AFIG as part of the arrangement.

16:15 EST Commercial Metals acquires all assets of Roane Metals Group - Commercial Metals Company announced it has acquired all the assets of metal recycling company Roane Metals Group LLC. Roane is capable of processing approximately 85,000 tons of ferrous and non-ferrous materials annually at its two facilities located in Tennessee. The majority of volumes relate to obsolete ferrous scrap grades consumed by CMC's long product mills. The acquired assets are expected to enhance the security and supply of competitively priced inputs to CMC's steelmaking operations.

16:03 EST Zentek clarifies removal of Albany graphite deposit estimate from website - Zentek announced that, pursuant to a review by the Ontario Securities Commission of the company's continuous disclosure, at the OSC's request, the company has removed from its website reference to the material resource estimate for the Albany graphite deposit because the technical report entitled "Technical Report on the Preliminary Economic Assessment of the Albany Graphite Project, Northern Ontario, Canada" dated July 9, 2015 contains an economic analysis that is no longer reliable and can no longer be classified as current. Additionally, the Company has revised a corporate presentation on its website to: (i) remove statements related to the Albany Graphite Deposit that can no longer be supported; (ii) remove disclosure of potential international partnerships unless and until any such partnerships are publically announced; and (iii) address certain material factors and assumptions used to develop forward-looking information. The Company has also filed on SEDAR, as a material contract, a reciprocal supply agreement with Ekomed Global Inc., which, as a material contract, was due to be filed no later than the date of filing of the Company's Annual Information Form.

15:55 EST Four Seasons Education (Cayman) Inc (ADR trading halted, volatility trading pause

15:00 EST Eli Lilly says FDA broadens indication for Verzenio - Eli Lilly announced that the U.S. Food and Drug Administration approved an expanded indication for Verzenio, in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer at a high risk of recurrence. High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade. This expanded adjuvant indication removes the Ki-67 score requirement for patient selection, the company stated.

14:33 EST JBG Smith says first phase of Amazon headquarters remains on schedule - JBG Smith announced that work on the first phase of Amazon's new "National Landing" headquarters remains on schedule for a summer 2023 opening without interruption or delay. Amazon's new offices at Met Park will accommodate up to 14,000 Amazon employees, including the 8,000 workers that Amazon has already hired, the company points out. JBG Smith says it continues to partner with Amazon in planning for the second phase of the development, which is expected to encompass 3.3M square feet across three office buildings and The Helix. "We are greatly encouraged by Amazon's recently reaffirmed commitment to its second headquarters project and to hiring at least 25,000 workers at HQ2. This project continues to serve as a major catalyst for National Landing's transformation into a global hub of innovation and a vibrant mixed-use urban community," said JBG Smith CEO Matt Kelly.

13:03 EST Harbor Custom Development to effect 1-for-20 reverse stock split - Harbor Custom Development announced it will effect a 1-for-20 reverse stock split of its issued and outstanding shares of common stock. Harbor's stockholders voted to authorize a reverse stock split in a range of 1-for-3 to 1-for-25 on February 17, 2023, and Harbor's directors voted to authorize the exact ratio for the reverse split of 1-for-20 on February 27, 2023. On March 6, 2023, the Company's common stock will begin trading on a post-reverse split basis on the Nasdaq Capital Market under the existing symbol "HCDI." The new CUSIP number for the common stock following the reverse split will be 41150T306.

13:01 EST Baker Hughes reports U.S. rig count down 4 to 749 rigs

12:49 EST Toyota recalls certain 2022 and 2023 Tundra models - Toyota is conducting a safety recall involving certain 2022 and 2023 Tundra vehicles in the U.S. Approximately 130,000 vehicles are involved in this safety recall. "Some of the subject vehicles may be equipped with an optional Toyota genuine truck bed accessory tonneau cover that can detach from the vehicle while driving. A tonneau cover that detaches from a vehicle could increase the risk of a crash or injury... Owners of involved vehicles will be notified by late March 2023," the company stated. Reference Link

12:30 EST Embark Technology to explore range of potential strategic alternatives - Embark Technology disclosed that its board approved a process to explore, review and evaluate a range of potential strategic alternatives available to the company, including exploring alternative uses of the company's assets to commercialize its technology, additional sources of financing, as well as potential dissolution or winding up of the company and liquidation of its assets. "The Board's decision comes following an extended evaluation by the Company of alternative markets in which to commercialize its technology as well as an exploration, performed with the assistance of a financial advisor, of a potential sale of the Company," Embark said in a regulatory filing.

12:28 EST Volkswagen sees FY23 vehicle deliveries around 9.5M - Volkswagen Group anticipates that overall vehicle deliveries will rise to around 9.5M in 2023 primarily driven by the strong order backlog on hand as semiconductor supply and logistics chain issues should ease in the course of the year. Volkswagen Group expects sales revenues to be 10 to 15% higher than the prior-year figure. In terms of operating result for the Group, an operating return on sales in the range of 7.5% to 8.5% is forecast for 2023. In the Automotive Division, the R&D ratio is expected to come in at around 8%, and the ratio of capex to sales revenue at around 6.5%. Volkswagen Group expects a strong increase in reported net cash flow in 2023. Net liquidity is expected to range between EUR35B and EUR40B; this includes the inflows and outflows of funds in connection with the payment of the special and regular dividend of EUR11B both due in 2023. The return on investment is expected to be between 12% and 15%. Challenges arise in particular from the economic environment, the increasing intensity of competition, volatile raw material, energy and foreign exchange markets, and stricter emission-related requirements.

12:00 EST V2X falls -9.0% - V2X is down -9.0%, or -$4.44 to $45.13.

12:00 EST Eagle Bulk Shipping falls -15.0% - Eagle Bulk Shipping is down -15.0%, or -$9.82 to $55.86.

12:00 EST Heritage Insurance rises 22.2% - Heritage Insurance is up 22.2%, or 60c to $3.32.

11:52 EST Visa reports Febrary U.S. payments volume up 11% y/y - In a regulatory filing out earlier, Visa provided volume and transaction data for January and February 2023. As previously disclosed, in March 2022, Visa suspended operations in Russia February U.S. payments volume on a year-over-year basis was up 11%. Credit grew 10% and Debit grew 11%. February card not present volume on a year-over-year basis was up 12%, card not present volume excluding travel was up 10% and card present volume was up 9%. February payments volume year-over-year growth for several key international markets was moderately stronger than fiscal first quarter 2023 year-over-year growth. February cross-border volume excluding intra-Europe transactions was 148% of 2019, with card not present volume excluding travel at 180% of 2019. Total card present and card not present travel cross-border volume excluding intra-Europe transactions was 131% of 2019. January and February travel cross-border volume into and from our Asia Pacific region continued to improve relative to 2019 levels, while travel cross-border volume into the U.S. improved at a more modest pace. February global processed transactions grew 12% year-over-year.

11:25 EST LiveOne's paid memberships exceed 2M - LiveOne reports paid memberships grew by over 587K in the past 12 months and over 100K in the first two months of calendar 2023. Total members, including paid and ad-sponsored, are now at a record 2.85M.

11:05 EST Daseke COO Rick Williams to retire, Scott Hoppe to succeed - Daseke announced that EVP and COO Rick Williams will retire from his current position. Scott Hoppe, currently President and CEO of E.W. Wylie, a wholly owned subsidiary of Daseke, will succeed Mr. Williams, effective June 1, 2023. As EVP and COO, Mr. Hoppe will have responsibility for managing and enhancing Daseke's industry-leading scale in the specialized and flatbed trucking market and overseeing ongoing business transformation and optimization efforts across the company.

10:44 EST JBG Smith Properties down 7% after Amazon pauses HQ construction - Shares of JBG Smith Properties (JBGS) are sharply lower after Amazon.com (AMZN) confirmed to Bloomberg that it is pausing construction on its second headquarters in Arlington, Virginia. John Schoettler, Amazon's real estate chief, said Amazon remains committed to Arlington, where by 2030 Amazon has committed to spend $2.5B and hire 25,000 workers, according to Bloomberg's Matt Day. The construction moratorium will delay the company's full arrival in Arlington and coincides with Amazon's biggest ever job cuts, Day pointed out. Amazon and its developer, JBG Smith Properties, had for months been discussing modifying the PenPlace plans, the report noted. JBG Smith shares are down $1.17, or 7%, to $15.88 following the news. Reference Link

10:01 EST HPX Corp trading resumes

10:00 EST ChargePoint falls -7.9% - ChargePoint is down -7.9%, or -89c to $10.37.

10:00 EST C3.ai rises 17.9% - C3.ai is up 17.9%, or $3.81 to $25.12.

10:00 EST Heritage Insurance rises 26.8% - Heritage Insurance is up 26.8%, or 73c to $3.45.

09:47 EST HHRS Stock trading resumes

09:47 EST ChargePoint falls -9.2% - ChargePoint is down -9.2%, or -$1.04 to $10.22.

09:47 EST Samsara rises 13.3% - Samsara is up 13.3%, or $2.24 to $19.12.

09:47 EST Heritage Insurance rises 17.6% - Heritage Insurance is up 17.6%, or 48c to $3.20.

09:42 EST HHRS Stock trading halted, volatility trading pause

09:34 EST Astronics trading halted, volatility trading pause

09:28 EST Wildpack Beverage reports $7.2M in confirmed customer orders for February - Confirmed customer orders reached a new record in February, with a total of $7,206,225, representing a significant increase over the previous month. February confirmed customer orders indicate an annualized 12-month forward run rate of $86.5 million. The Company also confirmed 245 sales orders and successfully converted 54 new customers during the month, both new records. Total throughput in February was 28,019,901 cans, including filling throughput of 2,750,027 cans, 16,825,388 cans were brokered during the month and printed sleeve throughput of 4,527,049 sleeves, all record-breaking breaking throughputs respectively. The Company's decoration throughput was also notable, with a total of 3,917,437 cans decorated.

09:17 EST EzFill adds 10 fleet accounts in February - EzFill Holdings announced that it added 10 new fleet accounts during the month of February, bringing the year-to-date new fleet account number to 19. The new fleet accounts include companies in the following industries: home improvement, auto rental, pet grooming, care providers, food service and distribution, pool supplies and moving and storage. EzFill will provide regularly scheduled fuel deliveries for an aggregate of approximately 140 vehicles that are expected to add up to approximately 233,000 additional gallons of fuel delivered annually.

09:06 EST Treace Medical settles lawsuit against Fusion Orthopedics - Treace Medical Concepts announces with Fusion Orthopedics that they have reached an amicable resolution of the litigation between the parties. Treace Medical filed the lawsuit on March 29, 2022 against Fusion Orthopedics in the United States District Court for the District of Arizona, alleging patent, trademark, and copyright infringement, as well as various unfair trade practices based on Fusion Orthopedics' use, sale, and promotion of the Lapilock 4D Advanced Bunion Surgery, including false advertising and unfair competition. Fusion Orthopedics subsequently filed counterclaims against Treace Medical, requesting declaratory judgment of non-infringement and invalidity of the patents, declaratory judgment of invalidity of Treace Medical's LAPIPLASTY trademark, as well as various unfair trade practices based on Treace Medical's use, sale, and promotion of the Lapiplasty 3D Bunion Correction, including counterclaims of false descriptions and false advertising. In March 2023, the parties entered into an agreement to settle this matter. While the terms of the settlement are confidential, Treace Medical is pleased with the outcome.

08:50 EST Altamira Therapeutics reportsdata from Bentrio clinical study - Altamira Therapeutics reported that data from a recent peer-reviewed clinical study involving Bentrio nasal spray's residence time and other rheological properties demonstrated superiority vs. a saline control. "The data presented in this study indicate that AM-301 has a prolonged nasal residence time of up to 3.5 h compared to a saline control. AM-301 is a safe and well-tolerable medical device with features suitable for intranasal administration. Its nasal residence time and distribution encourage its use to protect nasopharyngeal areas. Two nasal spray applications per nostril provide no substantial benefit over a single spray with regards to coverage of the mucosal surface or nasal retention time....Importantly, the formulation also reached the oropharynx, remaining in place for up to 240 min compared with 60 min in the control group. This feature is particularly important, since airborne viruses and allergens come into contact with both the nasal mucosa and oropharyngeal cavity." The study was performed on eight healthy volunteers that were administered Bentrio or a classic saline nasal spray marked with a fluorescent agent to track the distribution within the nasal cavity and the nasal residence time for up to 240 minutes. Participants were administered a single dose or, in case of Bentrio, also a repeated dose at a different spray angle. Bentrio was found to be widely distributed in the lower to middle parts of the nasal cavity, which is where airborne allergen particles typically collect. The thin protective film was present for 210 minutes. There were no meaningful differences between single and repeated dose application of Bentrio, confirming that one puff is sufficient. In contrast, saline nasal spray showed a shorter nasal residence time of 60 minutes only. Bentrio's extended presence within the nasal cavity is achieved thanks to its special thixotropic properties: the formulation is a gel designed to adhere to the nasal mucosa for an extended time, whereas a saline solution is prone to rapid run-off. Bentrio's gel formulation becomes sprayable upon shaking it briefly prior to application. Bentrio's long nasal residence time is supporting the extended protective effect of the nasal spray as it could be observed in other studies, including grass pollen and house dust mite challenge studies. In the single dose saline spray control group, fluorescence disappeared within 60 minutes from the nose, whereas the groups using a single dose of Bentrio retained a detectable amount of fluorescence for up to 210 minutes on the middle and inferior turbinates. While nasal residence time was the main focus of the study, the presence of the fluorescence in the oropharynx was monitored for 240 minutes as well. Figure 2- Oropharyngeal Endoscopy, shows that fluorescence for all three groups started to appear in the throat five to ten minutes after administration. The finding that Bentrio does not slow down discharge from the nasal cavity to the throat, suggests that the protective film established by Bentrio within the nasal cavity does not interfere with mucociliary clearance, a normal, physiological process that helps the body to clear particles out of the nose for discharge via the digestive tract. The saline control group's fluorescence disappeared after 90-120 minutes versus the Bentrio groups which showed fluorescence for up to 240 minutes. The results of the study show that the rheological properties of the AM-301 formulation allow it to be sprayed once and effectively provide extended coverage and protection of the nasal mucosa without interfering with natural nasal clearance.

08:46 EST Liquidity Services partners with AIS to sell unused ethylene plant components - Liquidity Services has partnered with Aaron Industrial Solutions to sell unused components from a Linde Engineering ethylene plant on AllSurplus.com. The sale will take place over the course of a year and encompass a wide range of asset types across numerous industrial sectors, with items located in 17 countries spanning three continents.

08:34 EST NanoVibronix regains compliance with Nasdaq - NanoVibronix announced that the company received official notice from Nasdaq that the company has evidenced compliance with all applicable criteria for continued listing on Nasdaq, including the $1.00 bid price requirement. Accordingly, the previously announced Nasdaq listing matter has been closed.

08:33 EST Assure Holdings announces reverse stock split, 20 for 1 - Assure Holdings announced that it effected a reverse stock split of its shares of common stock, $0.001 par value, at a ratio of 20 for 1 that will become effective on March 4, 2023 at 12:01 a.m. Pacific Standard Time. Assure's common stock expected to begin trading on the NASDAQ Capital Market on a split-adjusted basis when the market opens on March 6, 2023, meaning that each twenty pre-split shares will represent one post-split share and the share price is expected to increase mechanically in proportion to the 20:1 ratio. Assure's common stock will continue to trade under its existing symbol "IONM". The new CUSIP number for the common stock following the Reverse Stock Split will be 04625J303.

08:32 EST Alpha Tau granted expanded radioactive license from Israeli Ministry of EP - Alpha Tau Medical announced that the Israeli Ministry of Environmental Protection, EP, has granted the Company an amended radioactive license in the main manufacturing floor of its production facility in Jerusalem, increasing the maximum allowable amount of Thorium-228 for use and possession to produce Alpha DaRT sources from 30 milliCurie to 100 milliCurie. This expanded license could support the production of up to 300,000 Alpha DaRT sources per year in this facility. In addition, the Company is also pleased to announce that it has received approvals from both the Israeli Ministry of Environmental Protection and the Animal Testing Council at the Israeli Ministry of Health for its pre-clinical radioactive laboratory at its Jerusalem headquarters, to conduct pre-clinical experiments utilizing mice and rats. Alpha Tau CEO Uzi Sofer commented, "As our clinical trials continue to expand at an ever-increasing pace, led by our flagship ReSTART multicenter cutaneous SCC pivotal study in the U.S. alongside multiple trials in internal organs, the tremendous need for ongoing expansion of our manufacturing capacity, both in the U.S. and in Israel, remains critical to ensuring a steady supply of our Alpha DaRT treatments. Likewise, we are continuously growing our manufacturing and quality assurance teams to enable us to meet our current and future goals for the foreseeable future. In addition, with the exploration of combinations between the Alpha DaRT and other cancer therapies remaining a cornerstore of our strategy, our ability to test such combinations in-house in our own pre-clinical lab will allow us to optimize such combinations efficiently and help us examine a variety of possible combination trials for exploration in people desperately suffering from metastatic cancers."

08:28 EST Despegar.com CFO Alberto Lopez Gaffney resigns - Despegar.com announced that Alberto Lopez Gaffney, the company's CFO, has tendered his resignation effective March 17. The company's board of directors has begun a search for a new CFO. In connection with Lopez Gaffney's resignation, the company also announced the appointment of Maria Bettina Zubin as interim CFO. Zubin has been the company's controller since 2018 and brings almost 30 years of accounting and financial experience in positions of increasing responsibility at large global companies.

08:15 EST Corning unveils EDGE Distribution System for connectivity - Corning Incorporated unveiled its newest connectivity solution, the EDGE Distribution System. Designed to meet the ever-growing demand for information processing in the cloud, this pre-engineered data center solution shortens installation time for server cabling by up to 70%, helps address shortages in skilled labor, and provides up to a 55% reduction in carbon footprint by minimizing materials and packaging.

08:09 EST Daxor CEO Feldschuh provides corporate update in letter to shareholders - Daxor issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 1, 2023 from CEO & President, Michael Feldschuh. "It is my pleasure to report on Daxor's results for the year ended December 31, 2022. For the fourth year in a row our operating business is experiencing continued growth and development - increasing revenues from commercialization, great progress in research and development for our next-generation systems set to launch this year, and a growing body of clinical evidence... I am pleased to report that in 2022 we made important breakthroughs building on our focus in each of these key areas. As of December 31, 2022, Daxor's net assets were $28,969,469 or $6.75 per share as compared to $21,152,719, or $5.24 per share at December 31, 2022. This 36.95% increase in the net asset value is primarily due to the continued appreciation in value in the Operating Division. The valuation of the Operating Division increased $9,500,000 to $26,000,000 on December 31, 2022. For the year ended December 31, 2022, Daxor had net dividend income of $223,916, and net realized gains on investment activity of $2,679,421... In 2023 Daxor plans on launching its program of new point-of-care blood volume analysis systems, developed under multiple contracts with the U.S. DOD as well as grants from the National Institutes of Health, a significant leap forward in our market-leading technology... Management anticipates that upon approval there will be significant interest and uptake of the new systems based upon preliminary discussions with clinicians helping to develop the technology as well as an increase in disposable kit sales driven by the speed and convenience of the new system. Daxor's next generation devices will also be eligible for Phase III funding awards and acquisition by branches of the military for their deployment to aid in combat casualty care as well as further development contracts... Accelerating commercialization is a priority for Company management, and in this area Senior Vice President Jean Oertel, a veteran from both Medtronic and Sensionics, has focused on recruiting top talent to the sales and clinical support team adding new territory managers/clinical support reps to the team to support the strong growth in accounts...Our Company, like much of the world, has faced increased costs due to inflation. To offset this Daxor has announced an increase of 8.4% for our disposable Volumex kits to $385 per test starting at the end of Q1 of 2023...Equally important is the progress that Daxor has made in the area of clinical outcomes utilizing our blood volume analyzer. The company anticipates the results of a pilot Randomized Control Trial in heart failure patients with BVA guided treatment to be released at the end of Q1 of 2023 by researchers from the Duke Clinical Research Institute. This trial is in addition to ongoing Phase I RCT work at two Veterans Administrative hospitals under NIH funding as well as an outpatient prospective trial being conducted at Geisinger Medical Center...The Company also announced in August 2021 that a promising research letter on the use of Daxor's BVA-100 analyzer on six COVID-19 patients at NYU Medical Center had been published in the prestigious Journal of Critical Care."

08:08 EST Skillful Craftsman announces $1M convertible note private placement - Skillful Craftsman Education Technology entered into a convertible note purchase agreement, under which the Company had sold and issued a convertible promissory note in a principal amount of $1M to certain investor. The Note will mature in one year following the issuance, bearing interest at the rate of 7% per annum which shall be payable on the maturity date. At any time after the issuance and before the maturity date, the Note is convertible, in whole or in part, into the ordinary shares of the Company at the option of the holder thereof. If the closing bid price of the Ordinary Shares as reported by Nasdaq exceeds the conversion price for at least five consecutive trading days, all of the outstanding balance shall be automatically converted into Ordinary Shares. The conversion price is initially US$1.82 per Ordinary Share, subject to adjustment as set forth in the Note. Unless previously converted, the Company shall repay the outstanding principal amount plus all accrued but unpaid interest on the maturity date. The Note shall be an unsecured general obligation of the Company. Additional information regarding the private placement and the Note will be included in a Form 6-K to be furnished to the U.S. Securities and Exchange Commission by Skillful Craftsman.

08:06 EST Phoenix Motor qualifies for clean vehicle credit under Inflation Reduction Act - Phoenix Motor announced the company is now a qualified manufacturer for the commercial clean vehicle credit under the Inflation Reduction Act. Phoenix Motorcars' all-electric commercial vehicle models weighing greater than 14,000 pounds gross vehicle weight rating, or GVWR, are eligible for up to $40,000 in tax credits. Tax credits for vehicles weighing less than 14,000 pounds GVWR are available up to $7,500. On January 1, the commercial clean vehicle credit became available to businesses and tax-exempt organizations for the purchase of new electric vehicles to incentivize the adoption of electric vehicles and support domestic production. Currently, there is no limit on the number of tax credits a business can claim.

08:04 EST Achieve Life Sciences presents Phase 3 ORCA-2 trial data - Achieve Life Sciences announced data from the Phase 3 ORCA-2 trial will be presented at the Society for Research on Nicotine and Tobacco Annual Meeting, being held in San Antonio, TX, March 1-4, 2023. Additional findings from the ORCA-2 trial, that evaluated cytisinicline as a treatment for smoking cessation, will be included in the "Novel Treatments for Smoking Cessation" session held today, March 3, 2023, at 3:15 p.m. CST. The presentation will be given by ORCA-2 Principal Investigator, Dr. Nancy Rigotti, Professor of Medicine at Harvard Medical School and Director, Tobacco Research and Treatment Center, Massachusetts General Hospital. Topline results from the ORCA-2 trial were reported in April 2022, demonstrating 6-8 times increased likelihood of smoking abstinence with 3mg cytisinicline dosed 3 times daily for a period of 6-weeks or 12-weeks compared to placebo in 810 adult U.S. smokers. The study population was approximately 52 years in age, smoked a pack of cigarettes a day, and had made 5 to 6 prior quit attempts. Additional analyses being reported confirm that successful abstinence was observed in subgroups of smokers who received cytisinicline, regardless of age, gender, smoking history, or previous quit attempts. Subjects who received either 6 or 12-weeks of cytisinicline treatment experienced consistently higher rates of abstinence. The improvement was observed by the second week of treatment, maintained weekly throughout study treatment and during the 24- week follow-up period, compared to those who received placebo. Study compliance was high with 82% of subjects completing the 12 weeks of treatment. No treatment-related serious adverse events were reported and the majority of adverse events were mild in all subjects. Achieve is currently conducting the final FDA-registration enabling Phase 3 ORCA-3 trial for smoking cessation and the Phase 2 ORCA-V1 trial evaluating cytisinicline for e-cigarette cessation. The Company continues to expect topline data results for both trials to be announced in the second quarter of 2023.

08:03 EST Ayala Pharmaceuticals announces continuation of RINGSIDE Phase 2/3 study - Ayala Pharmaceuticals announced that the Independent Data Monitoring Committee for its Phase 2/3 RINGSIDE study evaluating investigational new drug AL102 in desmoid tumors conducted a prespecified periodic review of data from the study and recommended that the study continue without modifications. Phase 3 of RINGSIDE is a double-blind, placebo-controlled, clinical trial enrolling up to 156 patients with progressive disease, comparing AL102 at 1.2 mg once-daily to placebo. The primary endpoint for Phase 3 is progression-free survival with secondary endpoints including objective response rate, duration of response, tumor volume reduction, and patient-reported Quality of Life measures.

08:01 EST Aadi Bioscience CEO Brendan Delaney resigns, Scott Giacobello named interim CEO - Aadi Bioscience announced that Brendan Delaney has resigned for personal reasons from his position as CEO, President, and member of the Board of Directors of the company. Scott Giacobello, currently the company's CFO, has been appointed to serve as Interim CEO and President in addition to his current responsibilities. In addition, Neil Desai, Ph.D., the Founder of Aadi Bioscience and its President and CEO prior to Delaney, continues to serve as the Executive Chairman and a member of the Board of directors and will assist with the leadership transition. The Board of Directors has initiated an executive search for a replacement CEO.

07:39 EST Rekor Systems awarded contract by Florida DOT for roadway data collection - Rekor Systems has been awarded a contract by the Florida Department of Transportation to provide portable data services for the agency's roadway network in District 3 and the City of Tallahassee. Rekor will collect and report vehicle classification data, including count and spot speed information, data that the Federal Highway Administration requires. The multi-year contract is valued at over $1.8M.

07:35 EST Tradeweb Markets reports February trading volume $27.4T - Tradeweb Markets reported total trading volume for February of $27.4T. Average daily volume for the month was a record $1.43T, an increase of 21.5% year-over-year.

07:34 EST Aptorum Group completes pre-IND discussions with the FDA regarding ALS-4 - Aptorum Group announced the completion of the pre-IND discussions with the FDA. ALS-4 is a small molecule anti-virulence drug targeting infections caused by Staphylococcus aureus, including but not limited to Methicillin Resistant Staphylococcus Aureus, or MRSA. Upon the completion of ALS-4's respective Phase I clinical trials in Canada, ALS-4 has been targeting to obtain the necessary IND clearance for Phase II clinical trials in the United States. The Pre-IND discussions with FDA focused on overall development plan in preparation for the IND application of ALS-4 targeting Acute Bacterial Skin and Skin Structure Infections initially. With the positive feedback on the overall development strategy from the US FDA, Aptorum is now proceeding towards the IND submission of ALS-4.

07:33 EST Verizon appoints Sowmyanarayan Sampath as CEO, Verizon Consumer Group - Verizon Communication announced a number of executive management changes designed to set a path for the company's future growth plans. "These appointments will develop and grow the next generation of our leadership teams as we unleash Verizon's full potential moving forward," said Verizon Chairman and CEO Hans Vestberg. "This is a significant step in the transformation we started four years ago to be customers' choice for the next generation of communications technology. We're elevating our performance by building on our network strength, increasing accountability, and further strengthening Verizon's competitive capabilities." As part of these changes, Vestberg has appointed Sowmyanarayan Sampath, currently leading Verizon Business Group, to Executive Vice President and CEO of Verizon Consumer Group.Kyle Malady, currently leading Global Networks & Technology, has been appointed Executive Vice President and CEO of Verizon Business Group. In his new role, Malady will continue VBG's wireline efficiency programs and build on its strong wireless growth momentum. Succeeding Malady, Joe Russo, currently Senior Vice President and Chief Network Officer, was named Executive Vice President and President of Global Networks and Technology. He will focus on delivering an exceptional network experience for customers by continuing to improve the industry's most reliable network and the industry's most aggressive spectrum deployment with C-Band, optimizing 5G, and driving network efficiencies.

07:09 EST Ritchie Bros. receives support from large shareholders regarding IAA deal - Ritchie Bros. (RBA) issued the following statement regarding the support it is receiving from many shareholders, including among the company's largest shareholders, as well as industry analysts regarding the acquisition of IAA, Inc. (IAA): "Vontobel Asset Management, which owns 2.15% of Ritchie Bros. shares, has joined many other Ritchie Bros.' shareholders, including a number of our largest shareholders, in publicly supporting the IAA acquisition. We thank Ritchie Bros. shareholders for their strong support, which has been expressed both publicly and in our private conversations. This shareholder support, the positive commentary from independent third-party industry analysts and the increase in Ritchie Bros. stock price since the transaction was announced are all evidence that shareholders and analysts share our enthusiasm for the benefits and upside opportunities that a Ritchie Bros. + IAA combination creates. Importantly, employees and customers are also excited about bringing Ritchie Bros. and IAA together. The Ritchie Bros. management team has a proven record of execution. Integration planning is progressing well, and we are confident in our ability to deliver even greater shareholder value with IAA. In addition to the support announced yesterday by Vontobel Asset Management, Independent Franchise Partners and Eagle Asset Management, who are also among Ritchie Bros.' largest shareholders, have publicly announced their support for the IAA acquisition. Independent third-party industry analysts also recognize the expected benefits and value creation opportunities enabled by the IAA acquisition."

07:07 EST Ritchie Bros. urges shareholders to vote 'for' all proposals on White proxy card - Ritchie Bros. (RBA) issued a letter reinforcing the outstanding value creation opportunity presented by the acquisition of IAA, Inc. (IAA) and highlighting support the company is receiving from many shareholders and independent third-party industry analysts. It urges all shareholders to vote "FOR" all proposals listed on the WHITE Proxy Card.

07:05 EST Cloopen announces ADS ratio change - Cloopen announced that it will change the ratio of its American depositary shares to Class A ordinary shares from one ADS representing two Class A ordinary shares to one ADS representing six Class A ordinary shares. For Cloopen's ADS holders, this ratio change will have the same effect as a 1-for-3 reverse ADS split. There will be no change to Cloopen's Class A ordinary shares. Furthermore, no physical action by ADS holders will be required to effect the ratio change, as the change will be effected on the books of the depositary. The effect of the ratio change on the ADS trading price on the New York Stock Exchange is expected to take place at the open of business on March 15. Any fractional ADSs will be sold and the net proceeds from the sale of fractional ADSs will be distributed to the holders entitled thereto.

07:03 EST Old Dominion reports operating metrics for February - Old Dominion reported certain less-than-truckload, or LTL, operating metrics for February. Revenue per day decreased 2.9% as compared to February due to a 12.4% decrease in LTL tons per day that was partially offset by an increase in LTL revenue per hundredweight. The change in LTL tons per day was attributable to a 10.1% decrease in LTL shipments per day and a 2.5% decrease in LTL weight per shipment. For the quarter-to-date period, LTL revenue per hundredweight and LTL revenue per hundredweight, excluding fuel surcharges, increased 12.1% and 8.6%, respectively, as compared to the same period last year.

06:46 EST Hibbett sees FY24 CapEx $60M-$70M - With the largest share of this investment focused on new store growth, remodels, relocations, new store signage and improving the consumer experience.

06:43 EST Hibbett CEO sees 'several headwinds' in FY24 - Mike Longo, President and CEO, stated, "As we look ahead to Fiscal 2024, we believe there are several headwinds including inflation, higher interest rates and a more promotional retail environment. We anticipate consumers will be more cautious in their discretionary spending and while we still feel our unique assortment of high demand footwear will drive traffic and sales, margins are expected to be negatively impacted. Hibbett has a proven business model and a strategy to leverage our model and extend our market reach. We will continue our store expansion efforts and believe there are significant opportunities to expand our coverage in more underserved areas in both existing and new markets. We look forward to the opportunities to continue building our Hibbett and City Gear brands and deliver greater value to our customers and shareholders in the future."

06:41 EST Verve Therapeutics reports new data from study of VERVE-201 - Verve Therapeutics reported new preclinical data in non-human primates demonstrating potent, durable and well-tolerated editing of the ANGPTL3 gene following administration of VERVE-201. To support advancement of VERVE-201 toward clinical development, Verve is evaluating the candidate in numerous preclinical studies and reported preclinical data in NHPs. VERVE-201cyn, the NHP surrogate of VERVE-201, was studied in 34 wild-type NHPs, across three groups: control, 1.5 mg/kg dose and 3.0 mg/kg dose. Key results showed: Mean whole liver DNA editing at the ANGPTL3 gene of 55% and 63% and mean blood ANGPTL3 protein reduction from baseline of 89% and 96%, at 1.5mg/kg and 3.0mg/kg doses, respectively, with durable effects observed out to six months following treatment. Decreased liver triglyceride mass, a nonclinical surrogate for hepatic fat accumulation, in NHPs treated with either 1.5 mg/kg or 3.0 mg/kg of VERVE-201cyn as compared to vehicle control, when assessed six months following treatment. VERVE-201cyn was well-tolerated with only transient impacts on alanine aminotransferase and aspartate aminotransferase that resolved by day 14 and there was no observed impact on total bilirubin levels. On-target ANGPTL3 editing was detected primarily in the liver, with a lower degree of ANGPTL3 editing in adrenal and spleen tissues and minimal ANGPTL3 editing elsewhere, consistent with the biodistribution of LNPs. In an additional study, Verve evaluated VERVE-201's potential in an LDL receptor-deficient NHP model designed to mimic the physiology of patients with HoFH. Patients with HoFH have severe or complete LDLR deficiency, which limits the ability of traditional LNPs to deliver base editing medicines to the liver. Verve has developed its proprietary GalNAc-LNP to allow for uptake via an additional receptor, the asialoglycoprotein receptor, which is expected to enable delivery independent of LDLR. Verve first developed LDLR-deficient NHPs, resulting in an increase in mean LDL-C from 55 to 458 mg/dL. Subsequent treatment in these NHPs with VERVE-201cyn at a dose of 3.0 mg/kg led to: Mean whole liver DNA editing at the ANGPTL3 gene of 60% and a mean 84% reduction in blood ANGPTL3 protein. Mean 46% decrease in LDL-C and a mean 54% decrease in circulating triglycerides. Verve also reported preclinical findings in Ldlr-knockout mice fed a high-fat Western diet, in which administration of VERVE-201mu, as compared to control, led to a 97% reduction in blood ANGPTL3 protein, a 47% reduction in LDL-C and a 72% reduction in triglycerides.

05:13 EST Boeing, GBA announce order for 15 737-9 airplanes - Greater Bay Airlines, or GBA and Boeing announced an order for 15 737-9 airplanes. The agreement also includes a commitment for five 787 Dreamliners to support GBA's long-term plan to launch international long-haul service.